Best Vitamin K2 in Canada (2026)
October 28, 2026Best Vitamin C in Canada (2026)
October 29, 2026Quick Summary
A new phase 2 trial gave 1,000 mg of oral vitamin C a day for a year to 109 people with early blood disorders — and it failed its main goal. The abnormal blood cells did not grow any more slowly than on placebo. But an exploratory look at survival over roughly three years favoured vitamin C, and serious side effects were less common. The researchers call this a clue, not a conclusion.
Here is a trial result that refuses to behave. It missed the very thing it was designed to measure — then produced a survival signal that made researchers sit up straight. The catch: the survival finding was not the trial’s main test. It was an exploratory extra.
| Topic | What the research shows |
|---|---|
| Trial | EVITA: phase 2, double-blind, placebo-controlled, 109 people with CCUS or lower-risk myeloid malignancies, in Denmark and the US |
| Dose | 1,000 mg oral vitamin C daily for 12 months, versus matching placebo |
| Main result | No significant difference in abnormal blood-cell growth — the primary endpoint was not met |
| Surprise | Exploratory survival analysis favoured vitamin C (hazard ratio 0.35); serious adverse events 33% versus 57% on placebo |
| Caveat | Exploratory, post hoc, small phase 2 trial — a phase 3 trial must confirm it |
The trial that missed its target — and still turned heads
EVITA enrolled people with clonal cytopenia of undetermined significance (CCUS) or lower-risk myeloid malignancies, including lower-risk myelodysplastic syndrome (MDS). These are early blood disorders in which abnormal blood-cell clones expand over time and may eventually progress to acute myeloid leukemia. For CCUS, no approved therapy aims to stop that progression; most people are simply monitored.
Participants were randomly assigned to 1,000 mg of oral vitamin C a day or an identical-looking placebo for 12 months, with nobody knowing who got what until the trial ended. More than half turned out to be vitamin C deficient at the start, a finding that surprised even the research team. Then the headline measurement landed with a thud: the growth rate of the abnormal clones — the primary endpoint — did not differ significantly between groups.
It did not end there. In follow-up over roughly three years, an overall survival analysis — planned before the study ended but not part of the original protocol — showed a marked advantage for vitamin C, with a hazard ratio of 0.35 (95% CI, 0.17–0.71). Serious adverse events were also less common with vitamin C, at 33% versus 57% on placebo. Gut side effects were uncommon, mostly esophagitis in the vitamin C arm, in 5% of participants.
Why researchers think vitamin C might matter here
The theory is not about vitamin C as a general tonic. It is about an enzyme called TET2, which helps regulate which genes are switched on or off in blood stem cells. Vitamin C acts as an essential helper for TET enzymes, and TET2 mutations are among the most common genetic changes in CCUS. The idea is simple: if TET enzymes are struggling because of a mutation, correcting a deficiency might support whatever TET activity remains.
That also explains the ordinary oral dose, rather than the high-dose intravenous vitamin C that has made headlines in cancer circles for decades. Earlier oral vitamin C trials in advanced cancers showed no benefit, but EVITA tested something different: early disease, a deficient population, and a dose chosen to keep blood levels steadily topped up. Blood work added a hint: inflammatory signalling molecules called cytokines shifted in the vitamin C group in ways linked to better outcomes, though this does not prove the shifts caused the survival difference.
What the results do NOT prove
An exploratory analysis in a 109-person phase 2 trial is not proof, and the researchers say so plainly. Co-principal investigator Kirsten Grønbæk has said the team cannot recommend vitamin C for this purpose right now, because a phase 3 trial is still needed — and in that larger trial, overall survival will be the primary endpoint, tested properly from the start.
There is also a puzzle the researchers openly admit they cannot yet explain: clonal growth was measured at 12 months, but the survival difference accumulated over a much longer follow-up. Until the phase 3 trial fills that gap, the survival signal stays exactly what the researchers call it: hypothesis-generating. None of this means vitamin C has been shown to prevent leukemia or treat a blood disorder.
What is vitamin C and how is it supposed to work?
Vitamin C, also known as ascorbic acid, is a water-soluble vitamin humans cannot make on their own, so it must come from food or supplements. It is needed to build collagen, the protein that holds connective tissue together, and it plays a role in wound healing, immune function, and helping the body absorb iron from plant foods. It also acts as an antioxidant, helping to limit damage from free radicals.
The best food sources are fruits and vegetables: half a cup of raw sweet red pepper provides about 95 mg, a medium orange about 70 mg, and kiwifruit, broccoli, strawberries, and Brussels sprouts are all strong sources. Five varied servings a day can supply more than 200 mg. In supplements, the most common form is plain ascorbic acid, which has equivalent bioavailability to vitamin C naturally found in foods. Other forms include sodium ascorbate, calcium ascorbate, and combination products such as Ester-C, but research has found no consistent blood-level advantage for fancier forms. Note too that absorption falls below 50% once doses pass 1 gram a day — a big reason more is not automatically better.
What are the side effects of vitamin C?
Vitamin C generally has low toxicity, and high intakes do not usually cause serious problems. The most common complaints are digestive: diarrhea, nausea, and abdominal cramps, caused by unabsorbed vitamin C sitting in the gut. These tend to show up at higher doses and usually ease when the dose comes down.
A few cautions deserve attention. High intakes raise concerns about kidney stones, especially for people with existing kidney problems, and the evidence is mixed — one reason EVITA excluded people with a history of kidney stones. Because vitamin C boosts iron absorption, people with hereditary hemochromatosis, a condition causing iron overload, should be cautious with high doses. It may also interact with certain chemotherapy drugs and radiation therapy, so anyone undergoing cancer treatment should talk to their oncologist before taking antioxidant supplements, especially in high doses.
How much vitamin C should you take?
For most healthy adults, the recommended dietary allowance is 90 mg a day for men and 75 mg a day for women, with smokers needing about 35 mg more. Most people who eat a varied diet with fruits and vegetables can meet that from food alone. The tolerable upper intake level for adults is 2,000 mg a day from food and supplements combined — long-term intakes above that may raise the risk of side effects.
Research doses depend entirely on the question being asked. Common-cold studies have typically used 200 mg to 1 gram a day, while EVITA used 1,000 mg a day for a year in people with a specific blood disorder under medical supervision. Those numbers are not a recommendation for the general public. The sensible starting point is your diet, then a conversation with a pharmacist or doctor about whether a supplement makes sense for you, and at what dose.
What should you look for on the label?
Start with the form and the dose. Plain ascorbic acid is well studied and usually the best value; if you have a sensitive stomach, a mineral ascorbate such as calcium ascorbate may be gentler, though evidence for a major absorption advantage is limited. Check that the dose per serving is stated clearly — avoid products that hide amounts inside a proprietary blend.
In Canada, look for a valid Natural Product Number (NPN) on the label. An NPN means Health Canada has licensed the product, having assessed it for safety, quality, and label claims. Third-party testing is another plus: a product naming an independent lab or certification gives more assurance than one that simply says “tested” with no details.
References
- Mikkelsen, S. U., et al. (2026). Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial. Cancer, 132(19), e70549. https://doi.org/10.1002/cncr.70549
- National Institutes of Health, Office of Dietary Supplements. (n.d.). Vitamin C: Health professional fact sheet. https://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/
- Cancer Network. (2026, October 26). Could oral vitamin C confer OS benefit in CCUS and lower-risk MDS? https://www.cancernetwork.com/view/could-oral-vitamin-c-confer-os-benefit-in-ccus-and-lower-risk-mds-
This article reports on recent health research and is for general information only — it isn’t medical advice and doesn’t replace your doctor, pharmacist, or another qualified professional. Study findings describe what researchers observed, not a promise of results, and nothing here claims any supplement can diagnose, treat, cure, or prevent a disease. These statements have not been evaluated by Health Canada. Check with a healthcare professional before starting any new supplement, especially if you’re pregnant, nursing, taking medication, or managing a health condition.
